Merck Still Suffering From NotPetya Ransomware
Posted by: Timothy Weaver on 08/01/2017 06:51 AM
[
Comments
]
Merck, the pharmaceutical giant, is still suffering from a malware attack that occurred June 27th.
Although Merck has not announced the cause, it is suspected to be a result of ransomware.
On July 28th, the company announced that the malware has affected worldwide manufacturing, research and sales operations, and was still impacting its ability to fulfill orders for some products in certain markets. The only division that Merck has been able to fully restore is their packaging division.
Merck has revealed that "The company’s external manufacturing was not impacted."
Security experts believe that the company was victimized by the NotPetya ransomware.
"When it comes to ransomware and how it takes hold in every organization, nothing surprises me anymore," says Eldon Sprickerhoff, founder and chief security strategist of eSentire. "Best practice in manufacturing environments will mandate a strong network segregation stance between corporate and industrial, but the reality is that there are always access overlaps."
The company has not announced when it is expected to re-start manufacturing such products as cancer drug Keytruda, anti-diabetes medication Januvia, and Hepatitis C drug Zepatier.
Source: Dark Reading
Although Merck has not announced the cause, it is suspected to be a result of ransomware. On July 28th, the company announced that the malware has affected worldwide manufacturing, research and sales operations, and was still impacting its ability to fulfill orders for some products in certain markets. The only division that Merck has been able to fully restore is their packaging division.
Merck has revealed that "The company’s external manufacturing was not impacted."
Security experts believe that the company was victimized by the NotPetya ransomware.
"When it comes to ransomware and how it takes hold in every organization, nothing surprises me anymore," says Eldon Sprickerhoff, founder and chief security strategist of eSentire. "Best practice in manufacturing environments will mandate a strong network segregation stance between corporate and industrial, but the reality is that there are always access overlaps."
The company has not announced when it is expected to re-start manufacturing such products as cancer drug Keytruda, anti-diabetes medication Januvia, and Hepatitis C drug Zepatier.
Source: Dark Reading
Comments
